An improved long-term sales target today revitalised GSK shares after their dismal 2024. The confidence in GSK’s drugs pipeline came alongside results pointing to top line growth between 3% and 5% in ...
Shares of Ibiden Co., Ltd. fell sharply by 15.6% after the company reported lower-than-expected earnings for its latest quarter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback